Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$5.2M
Filings
164
Firms Hired
6
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Client expense: $470,000 · Firm income: —
Matched citations: HR1672
Joe Fiandra Access to Home Infusion Act of 2025
2026 · third_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Client expense: $470,000 · Firm income: —
Matched citations: HR.4993
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1672
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.946
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: S.1862
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Client expense: $450,000 · Firm income: —
Matched citations: HR1672
Joe Fiandra Access to Home Infusion Act of 2025
2026 · second_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Client expense: $450,000 · Firm income: —
Matched citations: HR.4993
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1672
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.946
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: S. 1862
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1672
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.946
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: S.1862
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1672
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.946
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Client expense: $430,000 · Firm income: —
Matched citations: HR1672
Joe Fiandra Access to Home Infusion Act of 2025
2026 · first_quarter · Firm: Alnylam Pharmaceuticals, Inc.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Client expense: $430,000 · Firm income: —
Matched citations: HR.4993
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1672
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Source: Senate LDA